Ellen Gould Chadwick

Summary

Affiliation: Children's Memorial Hospital
Country: USA

Publications

  1. ncbi Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age
    Ellen Gould Chadwick
    Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Pediatr Infect Dis J 24:793-800. 2005
  2. ncbi Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results
    Ellen G Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 22:249-55. 2008
  3. ncbi Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy
    Ellen Gould Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    Pediatr Infect Dis J 28:215-9. 2009
  4. ncbi Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States
    Deborah Persaud
    Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Infect Dis 195:1402-10. 2007
  5. ncbi Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children
    Ram Yogev
    Division of Infectious Diseases, Children s Memorial Hospital, 2300 Children s Plaza, Box 155, Chicago, IL 60614, USA
    Antimicrob Agents Chemother 49:336-41. 2005
  6. ncbi Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors
    Brian L Robbins
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Antimicrob Agents Chemother 52:3276-83. 2008
  7. ncbi Mycobacterium gordonae bacteremia in an asymptomatic adolescent with acquired immunodeficiency syndrome
    Robert Garofalo
    Division of Infectious Diseases, Children's Memorial Hospital, Chicago, IL, USA
    Pediatr Infect Dis J 22:569-70. 2003
  8. ncbi Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole
    Judith A Guzman-Cottrill
    Division of Infectious Disease, Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Children's Memorial Hospital, Chicago, IL, USA
    Pediatr Infect Dis J 23:1059-61. 2004

Detail Information

Publications8

  1. ncbi Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age
    Ellen Gould Chadwick
    Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Pediatr Infect Dis J 24:793-800. 2005
    ..Few data are available regarding clinical outcomes or dosing requirements for the protease inhibitor ritonavir in human immunodeficiency virus (HIV)-infected children younger than under 24 months of age...
  2. ncbi Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results
    Ellen G Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 22:249-55. 2008
    ..To investigate pharmacokinetics, safety and efficacy of lopinavir/ritonavir (LPV/r)-based therapy in HIV-1-infected infants 6 weeks to 6 months of age...
  3. ncbi Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy
    Ellen Gould Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    Pediatr Infect Dis J 28:215-9. 2009
    ....
  4. ncbi Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States
    Deborah Persaud
    Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Infect Dis 195:1402-10. 2007
    ....
  5. ncbi Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children
    Ram Yogev
    Division of Infectious Diseases, Children s Memorial Hospital, 2300 Children s Plaza, Box 155, Chicago, IL 60614, USA
    Antimicrob Agents Chemother 49:336-41. 2005
    ..Considerable interpatient variability was seen for all pharmacokinetic parameters of amprenavir. The results of this study suggest that 20 mg of amprenavir/kg administered twice a day should be used in future pediatric studies...
  6. ncbi Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors
    Brian L Robbins
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Antimicrob Agents Chemother 52:3276-83. 2008
    ....
  7. ncbi Mycobacterium gordonae bacteremia in an asymptomatic adolescent with acquired immunodeficiency syndrome
    Robert Garofalo
    Division of Infectious Diseases, Children's Memorial Hospital, Chicago, IL, USA
    Pediatr Infect Dis J 22:569-70. 2003
    ..Illness related to M. gordonae infection ranges from localized infections to rare cases of disseminated disease. This report describes treatment of the first case of occult M. gordonae bacteremia in an adolescent with AIDS...
  8. ncbi Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole
    Judith A Guzman-Cottrill
    Division of Infectious Disease, Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Children's Memorial Hospital, Chicago, IL, USA
    Pediatr Infect Dis J 23:1059-61. 2004
    ..Fusarium endocarditis is a rare and usually fatal disease. We report an immunocompromised child who survived Fusarium solani endocarditis despite the in vitro resistance of the organism to all available antifungal agents...